600594.SHG Guizhou Yibai Pharmaceutical Co Ltd
- Market cap
- CNY 2.58B
- P/E
- -
- P/B
- 1.23x
- ROE
- -9.9%
- Dividend yield
- 1.11%
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is 600594.SHG undervalued?
Graham numberThe Graham number of Guizhou Yibai Pharmaceutical Co Ltd cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Guizhou Yibai Pharmaceutical Co Ltd fundamental analysis
No fundamental analysis for Guizhou Yibai Pharmaceutical Co Ltd yet.
Guizhou Yibai Pharmaceutical Co Ltd stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Guizhou Yibai Pharmaceutical Co Ltd
Guizhou Yibai Pharmaceutical Co., Ltd. researches, develops, produces, and sells novel pharmaceutical products in China. The company offers products in the form of capsules, tablets, granules, syrups, small-volume injections, freeze-dried powder injections, lyophilized powder injections, dripping pills, and oral solutions in the areas of tumor system, cerebrovascular and cardiovascular, respiratory system, rheumatic bone, digestive system, pediatric, anti-infection, anti-inf…
Full company profileGuizhou Yibai Pharmaceutical Co Ltd financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Guizhou Yibai Pharmaceutical Co Ltd annual financial statements (CNY; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 3.69B | 3.81B | 3.88B | 3.36B | 3.41B | 3.35B | 2.74B | 2.82B | 2.17B | 1.86B | 1.32B |
| Gross Profit | 2.80B | 2.84B | 2.81B | 2.63B | 2.70B | 2.60B | 1.92B | 1.88B | 1.32B | 1.11B | 716M |
| Operating Income | 464M | 466M | -778M | 239M | 316M | 315M | -376M | 137M | -312M | -93.6M | -125M |
| EBITDA | 660M | 709M | -531M | 413M | 484M | 496M | -179M | 347M | -122M | -117M | -166M |
| Net Income | 385M | 388M | -725M | 142M | 229M | 244M | -426M | 103M | -317M | -330M | -202M |
| EPS | 0.49 | 0.49 | -0.92 | 0.18 | 0.29 | 0.31 | -0.54 | 0.13 | -0.40 | -0.42 | -0.26 |
| Balance Sheet | |||||||||||
| Total Assets | 6.59B | 7.19B | 6.48B | 5.62B | 5.23B | 5.07B | 4.87B | 4.60B | 4.10B | 3.44B | 3.16B |
| Total Liabilities | 2.40B | 2.55B | 2.56B | 1.89B | 1.76B | 1.51B | 1.68B | 1.58B | 1.49B | 1.17B | 1.04B |
| Shareholders' Equity | 3.89B | 4.23B | 3.46B | 3.60B | 3.37B | 3.50B | 3.04B | 2.88B | 2.49B | 2.19B | 2.04B |
| Cash & Short-term Investments | 1.03B | 1.17B | 551M | 1.02B | 617M | 380M | 592M | 699M | 541M | 447M | 403M |
| Total Debt | 1.52B | 1.66B | 1.51B | 1.34B | 1.18B | 903M | 1.08B | 864M | 711M | - | - |
| Cash Flow | |||||||||||
| Operating Cash Flow | 381M | 682M | 214M | 363M | 367M | 934M | 345M | 378M | 86.9M | 257M | - |
| Capital Expenditure | 333M | 403M | 321M | 201M | 396M | 448M | 323M | 130M | 96.3M | 35.0M | 24.7M |
| Free Cash Flow | 48.1M | 279M | -107M | 161M | -29.1M | 486M | 22.4M | 247M | -9.45M | 222M | 82.4M |
| Ratios | |||||||||||
| ROE | 9.9% | 9.2% | -21.0% | 3.9% | 6.8% | 7.0% | -14.0% | 3.6% | -12.7% | -15.1% | -9.9% |
| ROA | 5.8% | 5.4% | -11.2% | 2.5% | 4.4% | 4.8% | -8.8% | 2.2% | -7.7% | -9.6% | -6.4% |
| Net Profit Margin | 10.4% | 10.2% | -18.7% | 4.2% | 6.7% | 7.3% | -15.6% | 3.7% | -14.6% | -17.7% | -15.3% |
| Debt to Equity | 0.39x | 0.39x | 0.44x | 0.37x | 0.35x | 0.26x | 0.35x | 0.30x | 0.29x | - | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Guizhou Yibai Pharmaceutical Co Ltd dividends
- Dividend yield
- 1.11%
- Forward dividend
- -
- Payout ratio
- -
- Ex-dividend date
- Jun 7, 2024
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | CNY 28.7M | 0.04 | - |
| 2024 | CNY 86.9M | 0.11 | - |
| 2023 | CNY 41.2M | 0.05 | 39.8% |
| 2022 | CNY 49.1M | 0.06 | - |
| 2021 | CNY 103M | 0.13 | 42.2% |
| 2020 | CNY 475M | 0.60 | 207.7% |
| 2019 | CNY 65.5M | 0.08 | 46.2% |
| 2018 | CNY 130M | 0.16 | - |
| 2017 | CNY 120M | 0.15 | 31.1% |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Last stock split: 20:10 on Jul 16, 2015.
Who owns Guizhou Yibai Pharmaceutical Co Ltd
- Insiders 30.74%
- Institutions 0.42%
- Public & others 68.84%
- Shares outstanding 792M
- Free float 580M
Guizhou Yibai Pharmaceutical Co Ltd company profile
- Company name
- Guizhou Yibai Pharmaceutical Co Ltd
- Ticker
- 600594.SHG
- ISIN
- CNE000001H03
- Exchange
- Shanghai Stock Exchange
- Listed since
- Mar 8, 2004
- Sector
- Healthcare
- Industry
- Pharmaceuticals
- Employees
- 4,832
- Fiscal year end
- December
- Address
- No. 220-1, Baiyun Avenue, Guiyang, China, 550008
- Phone
- 86 85 1847 05590
- Website
- gzcci.com
About Guizhou Yibai Pharmaceutical Co Ltd
Guizhou Yibai Pharmaceutical Co., Ltd. researches, develops, produces, and sells novel pharmaceutical products in China. The company offers products in the form of capsules, tablets, granules, syrups, small-volume injections, freeze-dried powder injections, lyophilized powder injections, dripping pills, and oral solutions in the areas of tumor system, cerebrovascular and cardiovascular, respiratory system, rheumatic bone, digestive system, pediatric, anti-infection, anti-inflammatory, gynecological, tonic, oncology, orthopedics, gastroenterology, andrology and urology. Guizhou Yibai Pharmaceutical Co., Ltd. was founded in 1995 and is based in Guiyang, China.
Guizhou Yibai Pharmaceutical Co Ltd management
8- Ms. Ya Qi DouVice Chairman, Accounting Supervisor & Deputy GM · born 1984
- Mr. Xianti ZengFinancial Director · born 1974
- Mr. Zhiwei Wang CPADeputy GM & Director · born 1970
- Mr. Jiang XianhongDeputy GM & Secretary to the Board · born 1985
- Mr. Zhou YiDeputy General Manager · born 1970
- Ms. Jian PuDeputy General Manager · born 1978
- Mr. Li Dong WangDeputy General Manager · born 1981
- Mr. Hua Wen WangDeputy General Manager · born 1973